MX2012000395A - Inmunogenos conservados de escherichia coli. - Google Patents

Inmunogenos conservados de escherichia coli.

Info

Publication number
MX2012000395A
MX2012000395A MX2012000395A MX2012000395A MX2012000395A MX 2012000395 A MX2012000395 A MX 2012000395A MX 2012000395 A MX2012000395 A MX 2012000395A MX 2012000395 A MX2012000395 A MX 2012000395A MX 2012000395 A MX2012000395 A MX 2012000395A
Authority
MX
Mexico
Prior art keywords
protein
upec
coli
conserved
fragments
Prior art date
Application number
MX2012000395A
Other languages
English (en)
Spanish (es)
Inventor
Laura Serino
Danilo Gomes Moriel
Maria Rita Fontana
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2012000395A publication Critical patent/MX2012000395A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2012000395A 2009-07-07 2010-07-07 Inmunogenos conservados de escherichia coli. MX2012000395A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22366409P 2009-07-07 2009-07-07
US29114009P 2009-12-30 2009-12-30
PCT/IB2010/001962 WO2011004263A2 (en) 2009-07-07 2010-07-07 Conserved escherichia coli immunogens

Publications (1)

Publication Number Publication Date
MX2012000395A true MX2012000395A (es) 2012-02-28

Family

ID=43429616

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000395A MX2012000395A (es) 2009-07-07 2010-07-07 Inmunogenos conservados de escherichia coli.

Country Status (12)

Country Link
US (1) US10988511B2 (OSRAM)
EP (1) EP2451833B1 (OSRAM)
JP (1) JP2012532600A (OSRAM)
CN (1) CN102666571A (OSRAM)
AU (1) AU2010269961A1 (OSRAM)
CA (1) CA2767536A1 (OSRAM)
ES (1) ES2662716T3 (OSRAM)
IL (1) IL217412A0 (OSRAM)
MX (1) MX2012000395A (OSRAM)
SG (1) SG177533A1 (OSRAM)
WO (1) WO2011004263A2 (OSRAM)
ZA (1) ZA201200412B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2755994A2 (en) * 2011-09-14 2014-07-23 Novartis AG Escherichia coli vaccine combination
US9017698B2 (en) * 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CL2014001126A1 (es) * 2014-04-29 2014-08-29 Univ Chile Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
CN106715458A (zh) * 2014-07-18 2017-05-24 华盛顿大学 癌症疫苗组合物及其使用方法
US10799573B2 (en) * 2016-03-30 2020-10-13 Regents Of The University Of Minnesota Pertussis vaccines and methods of making and using
WO2018145180A1 (en) * 2017-02-13 2018-08-16 Nowill Alexandre Eduardo Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
AU2019323944A1 (en) * 2018-08-23 2021-03-25 La Trobe University Compositions and methods for reducing bacterial aggregation
WO2020240268A1 (en) * 2019-05-31 2020-12-03 Universidad De Chile An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec)
EP3892290A1 (en) * 2020-04-08 2021-10-13 NUMAFERM GmbH Variants of hlya and uses thereof
EP4121086A1 (en) * 2020-03-18 2023-01-25 NUMAFERM GmbH Variants of hlya and uses thereof
CN115466732B (zh) * 2021-06-10 2024-09-03 宁夏医科大学 用于制备Hispidin的重组蛋白及其应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
ES2200016T3 (es) 1989-03-21 2004-03-01 Vical Incorporated Expresion de secuencias polinucleotidicas exogenas en un vertebrado.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
WO1991002805A2 (en) 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
WO1992011033A1 (en) 1990-12-20 1992-07-09 Arch Development Corporation Control of gene expression by ionizing radiation
SG46492A1 (en) 1991-03-01 1998-02-20 Minnesota Mining & Mfg 1-Substituted 2-substituted 1H-imidazo [4,5-c] quinolin-4-amines
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
AU2998597A (en) 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
JP2002502882A (ja) 1998-02-12 2002-01-29 アメリカン・サイアナミド・カンパニー インターロイキン−１２とともに処方された肺炎球菌および髄膜炎菌のワクチン
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
PT1075276E (pt) 1998-05-07 2008-01-22 Corixa Corp Composição adjuvante e métodos para sua utilização
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
IL144084A0 (en) 1999-02-03 2002-05-23 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles and methods of manufacture and use
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AU766635B2 (en) 1999-09-24 2003-10-23 Smithkline Beecham Biologicals (Sa) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
MXPA02003108A (es) 1999-09-25 2003-10-14 Univ Iowa Res Found Acidos nucleicos inmunoestimuladores.
AU3108001A (en) 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
PT1313734E (pt) 2000-09-01 2010-02-09 Novartis Vaccines & Diagnostic Derivados aza heterocíclicos e sua utilização terapêutica
DE60132937T2 (de) 2000-09-11 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur Herstellung von Benzimidazol-2-yl -Chinolinonderivaten
DE60132471T2 (de) 2000-09-26 2009-01-15 Idera Pharmaceuticals, Inc., Cambridge Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
AU2002255798A1 (en) 2001-04-03 2002-10-21 Biosynexus Incorporated An animal model for enteric pathogens
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
BR0214407A (pt) 2001-11-27 2004-10-19 Anadys Pharmaceuticals Inc Compostos, composições farmacêuticas e método de modulação das imunoatividades da citocina
DK1499311T3 (da) 2002-03-29 2010-03-08 Novartis Vaccines & Diagnostic Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
US7273852B2 (en) 2002-06-13 2007-09-25 The Research Foundation Of The City University Of New York Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
KR20050038631A (ko) 2002-08-23 2005-04-27 카이론 코포레이션 글리코겐 신타제 키나제 3의 피롤 기제 억제제
AU2003300021A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US20060089264A1 (en) * 2004-02-24 2006-04-27 Seungok Hong Method of heat treating HTc conductors in a large fabricated system
PL1742659T3 (pl) 2004-04-05 2013-08-30 Zoetis Services Llc Poddane mikrofluidyzacji emulsje typu olej w wodzie oraz kompozycje szczepionek
WO2005103073A2 (en) * 2004-04-27 2005-11-03 Intercell Ag Td antigens
NZ560929A (en) * 2005-02-18 2009-12-24 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
PL2351772T3 (pl) * 2005-02-18 2017-01-31 Glaxosmithkline Biologicals Sa Białka i kwasy nukleinowe z bakterii Escherichia coli związanej z zapaleniem opon mózgowo-rdzeniowych/posocznicą
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
US8148055B2 (en) * 2006-06-30 2012-04-03 Infineon Technologies Ag Method for developing a photoresist
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
WO2011080595A2 (en) * 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins

Also Published As

Publication number Publication date
JP2012532600A (ja) 2012-12-20
IL217412A0 (en) 2012-02-29
EP2451833A2 (en) 2012-05-16
ZA201200412B (en) 2014-06-25
US20120207776A1 (en) 2012-08-16
CA2767536A1 (en) 2011-01-13
CN102666571A (zh) 2012-09-12
ES2662716T3 (es) 2018-04-09
WO2011004263A3 (en) 2011-09-29
SG177533A1 (en) 2012-02-28
EP2451833B1 (en) 2018-01-17
WO2011004263A2 (en) 2011-01-13
WO2011004263A9 (en) 2011-07-28
US10988511B2 (en) 2021-04-27
AU2010269961A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
MX2012000395A (es) Inmunogenos conservados de escherichia coli.
DK1858919T3 (da) Immunogener fra uropathogen Escherichia coli
EA201991157A1 (ru) Доставка белков на основе бактерий, аттенуированных по вирулентности
WO2021226436A8 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
BR112018003469A2 (pt) composição, método para induzir uma resposta imune a e. coli patogênica extraintestinal, e, processo para produzir uma composição.
HK1212249A1 (en) Bioconjugates comprising modified antigens and uses thereof
BR112018001572A2 (pt) método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo.
WO2008020330A8 (en) Immunogens from uropathogenic escherichia coli
BR112016006589A2 (pt) composição, e composição de vacina
EA201691478A1 (ru) Новый полисахарид и его применения
WO2009104092A3 (en) Escherichia coli immunogens with improved solubility
Hu et al. A TonB-dependent outer membrane receptor of Pseudomonas fluorescens: virulence and vaccine potential
MX359315B (es) Vacuna de adn para usarse en pacientes con cancer pancreatico.
CO6670521A2 (es) Vacuna y m´todos para reducir una infección por campylobacter
MX2017016401A (es) Composiciones inmunogenas.
UA98506C2 (en) Attenuated mycoplasma gallisepticum strains
MY191842A (en) Expec glycoconjugate vaccine formulations
PL404229A1 (pl) Wyizolowany immunogenny antygen bakteryjny i jego zastosowanie w profilaktyce i leczeniu zakażeń wywołanych przez Gram-ujemne bakterie
WO2011025344A3 (ko) 소의 병원성 대장균의 부착인자가 형질전환된 약독화 살모넬라균 변이주 및 이를 포함하는 소의 대장균증 및 살모넬라균증의 예방 및 치료용 백신조성물
RU2012148482A (ru) ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФЛАГЕЛЛИНА
MX357431B (es) Vacuna contra garrapatas rhipicephalus.
BR112012011062A2 (pt) aplicações terapêuticas e de diagnóstico contra tripanossomose.
BR112021024189A2 (pt) Método para sintetizar um polissacarídeo de ramnose, produto, polissacarídeos estreptocócico sintético e de ramnose estreptocócico sintético, glicoconjugados estreptocócico e de ramnose estreptocócico, composição ou vacina imunogênica, célula hospedeira bacteriana, e, kit de partes
WO2013038385A3 (en) Escherichia coli vaccine combination
PL387913A1 (pl) Zastosowanie rekombinowanego białka lub przeciwciał rozpoznających to białko do wytwarzania kompozycji wykorzystywanej w profilaktyce lub leczeniu zwierząt, zwłaszcza gospodarskich

Legal Events

Date Code Title Description
FA Abandonment or withdrawal